{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T02:37:56Z","timestamp":1752460676411},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The Kingston General Hospital Garfield Kelly Cardiovascular Research Fund"},{"name":"The Kingston General Hospital\/Hotel Dieu Hospital Cardiac Program Research Award"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ijcard.2016.05.061","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T02:52:47Z","timestamp":1463194367000},"page":"25-26","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab"],"prefix":"10.1016","volume":"219","author":[{"given":"William F.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zardasht","family":"Oqab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey E.J.","family":"Seaborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma M.","family":"Hopman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazik","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Baranchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.05.061_bb0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","article-title":"Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy","volume":"125","author":"Raschi","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2016.05.061_bb0010","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2016.05.061_bb0015","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bies.20092","article-title":"VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection","volume":"26","author":"Storkebaum","year":"2004","journal-title":"BioEssays"},{"key":"10.1016\/j.ijcard.2016.05.061_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/CIRCULATIONAHA.109.929364","article-title":"Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery","volume":"122","author":"Storkebaum","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.05.061_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/88842","article-title":"Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration","volume":"28","author":"Oosthuyse","year":"2001","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.ijcard.2016.05.061_bb0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.hrthm.2016.02.006","article-title":"Reference values for time- and frequency-domain heart rate variability measures","volume":"13","author":"Sammito","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ijcard.2016.05.061_bb0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.05.061_bb0040","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1345\/aph.1H244","article-title":"Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension","volume":"40","author":"Dincer","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ijcard.2016.05.061_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjca.2014.08.023","article-title":"Hypertension due to antiangiogenic cancer therapy with VEGF inhibitors: is autonomic nervous system toxicity another possible mechanism?","volume":"30","author":"McIntyre","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.05.061_bb0050","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731630969X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731630969X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T21:27:51Z","timestamp":1536701271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731630969X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":10,"alternative-id":["S016752731630969X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.05.061","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.05.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}